
CLAIMS

1. A conjugate of formula (I):




(I);

or a pharmaceutically acceptable salt thereof, wherein:

a is 1 to 10;

L is



;

wherein:

~ is the point of attachment to the nitrogen atom; and

* ~ is the point of attachment to Bm; and

Bm is an antibody or an antigen binding portion thereof that is capable of specifically binding to CD33.

2. The conjugate of claim 1, or the pharmaceutically acceptable salt thereof, wherein a is 2 to 8.

3. The conjugate of claim 2, or the pharmaceutically acceptable salt thereof, wherein a is 3 to 5.

4. The conjugate of claim 1, 2, or 3, or the pharmaceutically acceptable salt thereof, wherein Bm is an antibody or an antigen binding portion thereof comprising a heavy chain variable region (VH) complementarity determining region (CDR) 1 (VH-CDR1), comprising the amino acid sequence as set forth in SEQ ID NO: 1, a VH-CDR2 comprising the amino acid sequence as set forth in SEQ ID NO: 2, a VH-CDR3 comprising the amino acid sequence as set forth in SEQ ID NO: 3, a light chain variable region (VL) CDR1 (VL-CDR1) comprising the amino acid sequence as set forth in SEQ ID NO: 5, a VL-CDR2 comprising the amino acid sequence as set forth in SEQ ID NO: 6, and a VL-CDR3 comprising the amino acid sequence as set forth in SEQ ID NO: 7.

5. The conjugate of claim 4, or the pharmaceutically acceptable salt thereof, wherein Bm is an antibody or an antigen binding portion thereof comprising a VH comprising the amino acid sequence as set forth in SEQ ID NO: 4 and a VL comprising the amino acid sequence as set forth in SEQ ID NO:8.

6. The conjugate of claim 4, or the pharmaceutically acceptable salt thereof, wherein Bm is an antibody comprising a heavy chain comprising the amino acid sequence as set forth in SEQ ID NO:9 and a light chain comprising the amino acid sequence as set forth in SEQ ID NO:10.

7. The conjugate of any one of claims 1 to 6, wherein the conjugate is of formula (I).

8. The conjugate of any one of claims 1 to 6, wherein the conjugate is the pharmaceutically acceptable salt of formula (I).

9. The conjugate of any one of claims 1 to 8, or the pharmaceutically acceptable salt thereof, wherein L is covalently bound to Bm through a sulfur atom in Bm.

10. A pharmaceutical composition comprising the conjugate of any one of claims 1 to 9, or the pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.

11. The conjugate of any one of claims 1 to 9, or the pharmaceutically acceptable salt thereof, for use in treating acute myeloid leukemia.

12. The conjugate of any one of claims 1 to 9, or the pharmaceutically acceptable salt


thereof, for use in treating myelodysplastic syndrome.

13. The conjugate of any one of claims 1 to 9, or the pharmaceutically acceptable salt thereof, for use in treating cancer.

14. The conjugate of claim 13, wherein the cancer is breast cancer, gastric cancer, lymphoma, acute myeloid leukemia, multiple myeloma, head and neck cancer, squamous cell carcinoma, or hepatocellular carcinoma.

15. The conjugate of any one of claims 1 to 9, or the pharmaceutically acceptable salt thereof, for use as a medicament.


16. A compound of formula (II):



(II);


or a pharmaceutically acceptable salt thereof.

17. The compound of claim 16, wherein the compound has the structure:



.


18. A compound of formula (III):




(III);

or a pharmaceutically acceptable salt thereof.

19. The compound of claim 18, wherein the compound has the structure:




20. A method of preparing the conjugate of any one of claims 1 to 9, or the pharmaceutically acceptable salt thereof, the process comprising reacting a binding moiety with a compound of formula (I-1):



(I-1);

or a pharmaceutically acceptable salt thereof, wherein:

L’ is



;


wherein:

 is the point of attachment to the nitrogen atom.

21. The method of claim 20, further comprising reducing the antibody or the antigen binding portion thereof prior to reacting the antibody or the antigen binding portion thereof with the compound of formula (I-1).


22. The method of claim 20, further comprising preparing the compound of formula (I-1) or the pharmaceutically acceptable salt thereof by a process comprising reacting the compound 18 with compound 19 to produce the compound of formula (I-1) or the pharmaceutically acceptable salt thereof; wherein

compound 18 is



, and

compound 19 is





.


23. The method of claim 21, further comprising preparing the compound of formula (I-1) or the pharmaceutically acceptable salt thereof by a processing comprising Scheme 2.

24. A process selected from the group consisting of:


(a) a process for preparing compound 14 comprising reacting compound 12 with compound 13, thereby producing compound 14; wherein


compound 12 is: ;


compound 13 is:  ; and

compound 14 is: ;


(b) a process for preparing compound 15 comprising converting compound 14 to compound 15; wherein


compound 14 is  ; and


compound 15 is: ;


(c) a process for preparing compound 16 comprising reacting compound 15 with a compound having the formula  to produce compound

16; wherein


compound 15 is:  ; and

compound 16 is:  ;

(d) a process for preparing compound 17 comprising reacting compound 16 with a compound having the formula:  , thereby producing compound 17; wherein


compound 16 is:  ; and

compound 17 is:

 ; and


(e) a process for preparing compound 18 comprising converting compound 17 to compound 18; wherein

compound 17 is:




; and

compound 18 is:




.


25. A compound selected from the group consisting of:




, wherein ND is a neodegrader compound and Bm is an antibody or antigen binding portion thereof;




;





;




;


;


;


, wherein ND is a neodegrader compound;

and 
; or a pharmaceutically acceptable salt of any one of the foregoing.